Todos Medical: Early Detection Saves Lives


CEO: Herman Weiss MD MBA
Chief Business Officer: Rami Zigdon
Chief Technology Officer: Udi Zelig
Money Raised: $4 million
Founded: 2010

We have all heard the buzzwords being thrown around in the tech world. Phrases like artificial intelligence (AI), machine learning, and many others. The advancements we have made are truly astounding, but it begs the question, if we have all this advanced tech, why aren’t we applying it where we need it most, in healthcare? The answer is, we are, but not enough.

Todos Medical is using AI to help detect a variety of cancers and other conditions, such as Alzheimer’s, early enough to increase the effectiveness of the treatment significantly. How many times have you heard about someone who was diagnosed early enough to have beaten the cancer, or tragically, the opposite and it was so late that the cancer spread uncontrollably – it was too late to act.

Now, in addition to the challenge of early detection of cancer, there are also other massive challenges facing the world of oncology. Using breast cancer as an example, current diagnostic tools have many worrisome characteristics, including false positive mammograms, unnecessary biopsies and difficult detection due to dense breast tissue.

Another basic and profound issue facing cancer diagnostics is patient compliance. Among patients recommended for colonoscopies, nearly 50% of tests ordered are not actually conducted due to the uncomfortable nature of the procedure, which also applies to stool tests. Imagine, if you will, the benefits society would be afforded if colon cancer screens were increased by 100%!

Stepping away from the cancer world, when it comes to another horrible disease, Alzheimer’s, there is still no effective early detection of the disease. With all the technology of the 21st century, there has yet to be a drug approved to treat Alzheimer’s, primarily because of the costs associated with clinical trials and patient recruitment, as well as recruiting patients too late in their disease progression.

Todos is attempting to address all of these challenges and more. So how does it work?

The immune-oncology space has clearly identified the fact that different cancers interact differently with the host’s immune system. Working with complex algorithms which are aided by artificial intelligence, the company is able to identify the unique fingerprint of cancers at an early stage.

Utilizing “Immune-diagnostics” via simple blood tests, Todos is able to detect the cancer’s “immune fingerprint” at its early stage, helping physicians identify the appropriate patients to do further tests for cancer and eventually treat it, at a much more curable stage, which will help more patients live cancer free.

Todos’s tech (TBIA), licensed and developed out of Ben-Gurion University, is a simple blood test for cancer detection. The blood is separated into two components – immune cells and plasma and then is measured by infra-red spectroscopy for total biochemical analysis of both components. The TBIA concept is – instead of observing specific proteins or other components released from the tumor, when the cancer is more advanced – looking at the entire biochemical composition of the immune system and the plasma and learning the characteristic features related to cancer patients in comparison to healthy the population, and can tell what is worrisome and what is not.

Continue reading at Jerusalem Post.

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.